One in Two: A Manchester Cancer Research Podcast
Season 2 - Lung Cancer: From basic biology to transformative therapies
The basic biology of lung cancer with Dr Colin Lindsay: Exploring oncogenic drivers such as the KRAS mutation
With one in two of us receiving a cancer diagnosis at some point during our lives, it has never been more important to improve the outcomes for people affected by cancer.
In this episode, we speak to Dr Colin Lindsay, Clinical Senior Lecturer at The Christie and The University of Manchester about the basic biology of lung cancer, focusing on:
- The high incidence of lung cancer here in Manchester
- The differences between non-small cell and small-cell lung cancer
- Oncogenic drivers in lung cancer such as the KRAS mutation
- His work on the drug sotorasib which targets KRAS mutant cancer and has now been approved by the FDA and for use in the UK by NICE
It’s always the patients that teach me and they as so impressive, absolutely all of them in different ways. I'm not a person that's easily surprised, but it’s really the patients that surprise me because they're just so gracious with their time and their energy when they've got far more important things to focus on. It really is a privilege to see these patients, whose lives are totally disrupted, opening up to us and we are doing our best to help them.
Dr Colin Lindsay
Clinical Senior Lecturer in Medical Oncology at The University of Manchester
Dr Colin Lindsay
Dr Colin Lindsay is a Clinical Senior Lecturer in Medical Oncology, also working at the Christie NHS Foundation Trust to divide his time 50/50 between research and the clinic.
Colin trained at the CRUK Beatson Institute and Cancer Centre in Glasgow, where he completed a PhD under Owen Sansom, studying genetically-modified mouse models of RAS- and RAF-driven melanoma. Following that he changed focus to lung cancer translation through involvement with the CRUK Stratified Medicine Programme, as well as a two year ESMO translational fellowship with Benjamin Besse and Jean-Charles Soria at the Gustave Roussy Institute in Villejuif, France.
His main research interests are 1) the implementation of effective treatment strategies for cancers driven by RAS mutation, and 2) successful and efficient translation of genomic results for optimal clinical gain.